Last reviewed · How we verify

HL036 Ophthalmic Solution — Competitive Intelligence Brief

HL036 Ophthalmic Solution (HL036 Ophthalmic Solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Ophthalmology.

phase 3 Ophthalmology Biologic Live · refreshed every 30 min

Target snapshot

HL036 Ophthalmic Solution (HL036 Ophthalmic Solution) — HanAll BioPharma Co., Ltd.. HL036 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HL036 Ophthalmic Solution TARGET HL036 Ophthalmic Solution HanAll BioPharma Co., Ltd. phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HL036 Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/hl036-ophthalmic-solution. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing